摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Chloro-4-(2-chloro-phenyl)-butan-2-ol | 59363-10-9

中文名称
——
中文别名
——
英文名称
1-Chloro-4-(2-chloro-phenyl)-butan-2-ol
英文别名
1-Chloro-4-(2-chlorophenyl)butan-2-ol
1-Chloro-4-(2-chloro-phenyl)-butan-2-ol化学式
CAS
59363-10-9
化学式
C10H12Cl2O
mdl
——
分子量
219.111
InChiKey
ZLNMVUJQAQMVBO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

文献信息

  • [EN] HIGH PURITY BUTOCONAZOLE NITRATE WITH SPECIFIED PARTICLE SIZE AND A PROCESS FOR PREPARATION THEREOF<br/>[FR] BUTOCONAZOLE NITRATE DE HAUTE PURETE PRESENTANT UNE TAILLE PARTICULAIRE SPECIFIEE, ET SON PROCEDE DE PREPARATION
    申请人:RICHTER GEDEON VEGYESZET
    公开号:WO2005070897A1
    公开(公告)日:2005-08-04
    One object of the invention is high purity butoconazole nitrate of the formula (I) (I) containing maximum 0.1 wt % of chemical impurities, wherein at least 95% of the particles of the substance are below 75µm by diameter, whereas at least 99% of the particles are below 250µm by diameter, and process for its preparation. A pharmaceutical composition comprising as active ingredient, high purity butoconazole nitrate of specified particle size in admixture with known auxiliaries is also within the scope of the invention.
    本发明的一个目标是具有化学式(I)(I)的高纯度硝酸布托康唑,其化学杂质含量最大为0.1重量%,其中至少95%的颗粒直径小于75µm,而至少99%的颗粒直径小于250µm,以及其制备方法。本发明还涵盖了一种包含作为活性成分的特定粒径高纯度硝酸布托康唑与已知辅助剂混合的制药组合物。
  • High Purity Butoconazole Nitrate with Specified Particle Size and a Process for the Preparation Thereof
    申请人:Czibula Laszlo
    公开号:US20080221190A1
    公开(公告)日:2008-09-11
    One object of the invention is high purity butoconazole nitrate of the formula (I) (I) containing maximum 0.1 wt % of chemical impurities, wherein at least 95% of the particles of the substance are below 75pm by diameter, whereas at least 99% of the particles are below 250 μm by diameter, and process for its preparation. A pharmaceutical composition comprising as active ingredient, high purity butoconazole nitrate of specified particle size in admixture with known auxiliaries is also within the scope of
    本发明的一个目标是高纯度的丁康唑硝酸盐,其化学式为(I)(I),最大含量为0.1重量%的化学杂质,其中至少95%的物质粒子直径在75pm以下,而至少99%的物质粒子直径在250μm以下,以及其制备方法。还包括一种制药组合物,其中包括所述的特定粒径的高纯度丁康唑硝酸盐与已知辅助剂混合而成的活性成分。
  • High purity butoconazole nitrate with specified particle size and a process for preparation of thereof
    申请人:RICHTER GEDEON VEGYÉSZETI GYÁR RT
    公开号:EP1903035A2
    公开(公告)日:2008-03-26
    One object of the invention is high purity butoconazole nitrate of the formula (I) (chemical name: 1-[4-(4-chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl]-imidazole nitrate) containing maximum 0.1 wt % of chemical impurities, wherein at last 95 % of the particles of the substance are below 75 µm by diameter, whereas at least 99 % of the particles are below 250 µm by diameter. Another object of the invention is a process for the preparation of butoconazole nitrate starting from 1-chloro-4-chlorophenyl-2-butanol and imidazole to yield a compound of the formula (IV), reacting said compound of formula (IV) with thionyl chloride to give a compound of the formula (V) and reacting the obtained compound of the formula (V) with 2,6-dichlorothiophenol, performing said reaction steps in such a manner that the first step is carried out in a mixture of a water immiscible solvent and an aqueous solution of an alkali metal hydroxide or carbonate in the presence a phase transfer catalyst; the second step is accomplished in 1,2-dichloroethane solvent in the presence of dimethylformamide, whereas 1-1.2 mol of thionyl chloride reactant is used based on the amount of the compound of the formula (IV); and the third steps is performed without isolation of the product (VI) from the solution obtained, but to said solution nitric acid is added to give the butoconazole nitrate salt. Still another object of the invention is a process for the preparation of the compound with the above specified particle size starting from crude butoconazole nitrate in such a manner that the starting material is dissolved in a mixture of methanol and methyl isobutyl ketone of 1 - 1.5 : 1 ratio (v/v), this solution is then added to methyl isobutyl ketone cooled to a temperature between 5 °C and -15 °C and the product obtained is isolated. A pharmaceutical composition comprising as active ingredient high purity butoconazole nitrate of specified particle size in admixture with known auxiliaries is also within the scope of the invention.
    本发明的一个目的是式(I)的高纯度硝酸丁康唑(化学名称:1-[4-(4-氯苯基)-2-(2,6-二氯苯基)-正丁基]-咪唑硝酸盐),其化学杂质含量不超过0.1重量%,其中至少95%的物质颗粒直径低于75微米,而至少99%的颗粒直径低于250微米。本发明的另一个目的是制备硝酸丁康唑的工艺,从 1--4-氯苯基-2-丁醇咪唑开始,得到式 (IV) 化合物,将所述式 (IV) 化合物与亚硫酰氯反应,得到式 (V) 化合物,将得到的式 (V) 化合物与 2、6-二苯硫酚反应,第一步在不溶于的溶剂和碱属氢氧化物或碳酸溶液的混合物中,在相转移催化剂存在下进行;第二步在有二甲基甲酰胺存在的 1,2-二氯乙烷溶剂中完成,而 1-1.2摩尔的亚硫酰氯反应物;第三步不从所得溶液中分离产物(VI),但在所述溶液中加入硝酸,得到硝酸丁康唑盐。 本发明的另一个目的是以硝酸丁康唑粗盐为起始原料制备具有上述粒度的化合物的工艺,其方法是将起始原料溶解在甲醇甲基异丁基酮的混合物中,其比例为 1 - 1.5 : 1 (v/v),然后将该溶液加入甲基异丁基酮中,冷却至 5 °C 至 -15 °C 之间,分离得到产物。 一种药物组合物也属于本发明的范围,该药物组合物包括作为活性成分的高纯度硝酸丁康唑和已知的助剂,其粒径为规定的粒度。
  • HIGH PURITY BUTOCONAZOLE NITRATE WITH SPECIFIED PARTICLE SIZE AND A PROCESS FOR PREPARATION THEREOF
    申请人:RICHTER GEDEON VEGYESZETI GYAR RT.
    公开号:EP1709005A1
    公开(公告)日:2006-10-11
  • US7625935B2
    申请人:——
    公开号:US7625935B2
    公开(公告)日:2009-12-01
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫